1. Scrip
  2. >>Business
  3. >>Financing

Year Ahead Could Prove Rough For Private Biotech Financing

Financing Forecast: Industry Experts Have Grim Outlook For Private Biotechs

 
• By Alaric DeArment

The second half of 2022 saw a downturn in fundraising by venture capital firms, and panelists at BIO CEO said that could spell trouble in 2023.

• Source: Shutterstock

By most measures, 2022 was a good year for venture capital funds that invest in health care companies, with the total amount of capital raised last year coming in second only to the record-setting figure for 2021. But the strength of the year was front-end loaded and the amounts raised by health care investment firms declined in both the number of new funds and dollar figures during the last two quarters of 2022, falling below the quarterly average for 2020.

Consequently, speakers on a panel at the Biotechnology Innovation Organization’s BIO CEO & Investor Conference said they see difficult times...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By Andy Smith

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By Aakash Babu

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.